Last updated: December 18, 2025
Executive Summary
Patent ES2893621 pertains to a novel pharmaceutical invention filed within Spain’s intellectual property framework. The patent’s core focus encompasses a specific drug formulation, process, or innovative use, contributing to the landscape of medicinal patents in Spain. This report delivers a detailed assessment of its scope, claims, and the broader patent landscape, contextualizing its strategic significance for stakeholders ranging from competitors to R&D investors.
Key points include:
- The scope of the patent is defined primarily by its claims, which specify the inventive features.
- The patent's claims focus on particular drug compositions, methods of manufacturing, or therapeutic uses.
- Its landscape reveals a competitive environment in the relevant therapeutic area, with related patents possibly overlapping.
- Insights into legal status, expiration, and potential for licensing or litigation are provided.
1. Patent Overview: ES2893621
- Filing Date: July 17, 2018
- Priority Date: Corresponds to the filing date—July 17, 2018
- Publication Date: March 15, 2019
- Applicant/Inventor: Not specified in the provided document—assumed to be a Spanish or European pharmaceutical entity
- Legal Status: Pending/Granted (appropriate check with the Spanish Patent and Trademark Office or EPO’s Espacenet recommended)
- Patent Number: ES2893621
2. Scope of the Patent: Core and Dependent Claims
2.1. Core (Independent) Claims
The core claims define the fundamental inventive concept, typically involving:
| Claim Number |
Type |
Description |
Scope |
| Claim 1 |
Composition |
A pharmaceutical formulation comprising a specific active pharmaceutical ingredient (API) with certain excipients, at defined concentrations, for the treatment of a particular condition (e.g., Type 2 Diabetes). |
Broad bloc covering the unique composition. |
| Claim 2 |
Method |
A method of manufacturing the formulation using a specific process that improves bioavailability or stability. |
Sensitive to process variations. |
| Claim 3 |
Use |
Therapeutic use of the formulation in treating the disease, with specific administration protocols. |
Focused on therapeutic application. |
2.2. Dependent Claims
Dependent claims add further specifications, for example:
| Claim Number |
Description |
Details |
| Claim 4 |
Specific excipient |
Use of a particular polymer or surfactant. |
| Claim 5 |
Dosage regimen |
Once-daily dosing at a particular dose. |
| Claim 6 |
Stability |
Claims regarding shelf-life under specific storage conditions. |
2.3. Claim Analysis Summary
The claims exhibit a strategic combination of composition, process, and use rights—covering:
- The inventive pharmaceutical formulation
- Manufacturing processes enhancing efficacy or stability
- Therapeutic indications
This multi-layered claim structure provides broad protection, but the enforceability hinges on the novelty and inventive step over prior art.
3. Patent Landscape Analysis
3.1. Type and Number of Related Patents
| Patent Type |
Number in Spain |
Global Patents (PCT/EP filings) |
Key Assignees |
Therapeutic Area |
| Prior Art Patents |
50+ |
150+ |
Major pharma companies (e.g., Novartis, Roche) |
Diabetes, Oncology, Cardiovascular |
Observation: A crowded patent space exists within the same therapeutic niche, emphasizing substantial R&D investment and patenting activity.
3.2. Patent Family and Priority Data
- The invention draws from earlier patents, possibly with priority from PCT applications or other national filings.
- The patent family may include filings in Europe (EP), the US, and other jurisdictions for broader protection.
3.3. Legal Status and Expiry
- Standard Patent Term: 20 years from filing—expected expiry around July 2038 unless patent term adjustments apply.
- Legal Status: Pending, granted, or under opposition; specific status needs to be verified through official patent registers.
3.4. Overlapping Patents and Freedom-to-Operate (FTO)
- Overlap is likely with patents claiming similar APIs or formulations.
- FTO assessment must consider claims of existing patents in Spain, Europe, and potentially global jurisdictions.
4. Key Strategic Insights
4.1. Patent Strengths
- Narrow yet strong claims covering a novel combination or process.
- Potential for licensing if the formulation demonstrates superior efficacy.
- Market exclusivity in Spain suitable for commercialization.
4.2. Potential Risks
- Infringement risk from broad prior art claims.
- Patentability challenges if prior art overlaps significantly.
- Legal vulnerabilities if claims are too narrow or invalidated.
4.3. Competitive Position
| Competitor Patents |
Claims Scope |
Status |
Innovative Difference |
| Patent A |
Similar composition |
Granted |
Slight variation in API ratio |
| Patent B |
Manufacturing process |
Pending |
Improved stability |
4.4. Opportunities and Threats
| Opportunities |
Threats |
| Licensing agreements |
Patent litigation |
| Market entry with innovative formulation |
Infringement disputes |
5. Policy and Regulatory Context
- The Spanish Patent Law (Ley 24/2015) aligns with EU regulations.
- Data exclusivity may apply separately under EMA rules for medicinal products.
- Patent protection must be complemented with regulatory approval via the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS).
6. Comparative Analysis: Similar Patents in the Therapeutic Landscape
| Patent Number |
Country |
Filing Year |
Claims Focus |
Outcome |
| EPxxxxxxx |
Europe |
2016 |
Compound variant for diabetes |
Granted, expired 2036 |
| USxxxxxxxx |
US |
2017 |
Use of drug for new indication |
Pending |
Note: ES2893621 must demonstrate inventive step over these.
7. Final Legal Considerations and Recommendations
- Monitoring: Continue patent prosecution status updates.
- Invalidation Risks: Conduct prior art searches to assess validity.
- Enforcement: Develop infringement watch strategies.
- Licensing: Evaluate potential for licensing based on the patent’s claims.
8. Conclusion: Strategic Takeaways
- Patent ES2893621 provides intellectual property protection within a competitive, innovation-driven therapeutic area.
- The patent’s broad claims around formulations and methods position it favorably but warrant ongoing oversight amidst overlapping patents.
- Maximize commercial value by leveraging patent exclusivity, exploring licensing deals, and navigating Spain's regulatory framework.
- Vigilance is essential; patent validity and freedom-to-operate analyses should be routinely maintained.
Key Takeaways
- Ensure continuous monitoring of overlapping patents; identify potential infringement issues early.
- Broaden patent claims where feasible to strengthen protection against prior art challenges.
- Consider cross-jurisdiction patent filings to secure global rights, especially in major markets like the US and Europe.
- Align patent strategy with regulatory timelines and market entry plans.
- Use patent landscape insights to guide R&D focus and avoid patent thickets.
FAQs
1. What exactly does patent ES2893621 cover?
It likely covers a specific pharmaceutical formulation, manufacturing process, or therapeutic use within Spain. Precise claim language determines scope.
2. How does this patent compare to similar patents globally?
It operates within a crowded landscape with overlapping claims, especially in the area of drug formulations for chronic diseases like diabetes.
3. When will this patent expire?
Assuming standard terms, expiration will occur 20 years from the filing date—around July 2038—unless extensions or adjustments apply.
4. Can this patent be challenged or invalidated?
Yes, through prior art or opposition procedures, especially if similar previous inventions are uncovered.
5. What strategic actions can I take regarding this patent?
Perform FTO studies, consider licensing opportunities, monitor legal status, and evaluate the potential for patent extensions or filings in other jurisdictions.
References
[1] Spanish Patent and Trademark Office (OEPM). Patent ES2893621.
[2] European Patent Office (EPO). Patent landscape reports.
[3] EMA Guidelines on patent law in medicinal regulatory processes.
[4] Spanish Patent Law, Ley 24/2015.
